Varicella zoster virus (VZV) vaccine

A messenger ribonucleic acid (mRNA) vaccine comprising;

• (a) an mRNA polynucleotide comprising from 5′ to 3′ a 5′untranslated region UTR, an open reading frame (ORF) encoding a varicella zoster virus (VZV) glycoprotein E(gE) protein, the protein comprising an amino acid sequence of SEQ ID NO:
• 38, a protein comprising a Y569A or a Y582G mutation, relative to the amino acid sequence of SEQ ID NO:
• 10, a protein comprising a truncated polypeptide lacking the cytoplasmic tail domain shown in amino acids 574-623 of SEQ ID NO:
• 10, or a truncated polypeptide lacking the transmembrane anchor domain shown in amino acids 562-573 of SEQ ID NO:
• 10 and a 3′ UTR, wherein 100% of uracil nucleosides in the ORF of the mRNA polynucleotide are N1-methylpseudouridine;
• and
• (b) a lipid nanoparticle comprising 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), PEG-distearoyl glycerol (PEG DMG) and a compound of Formula (I):
• or a salt thereof, wherein:
• R1 is selected from the group consisting of C5-30 alkyl, C5-20 alkenyl, and —R″M′R′;
• R2 and R3 are independently selected from the group consisting of C1-14 alkyl and C2-14 alkenyl;
• R4 is —(CH2)nQ, wherein Q is-OR, and n is selected from 1, 2, 3, 4, and 5;
• each R5 is H;
• each R6 is H;
• M and M′ are independently selected from —C(O)O— and —OC(O)—;
• R7 is H;
• R is H;
• R′ is selected from the group consisting of C1-18 alkyl and C2-18 alkenyl;
• R″ is selected from the group consisting of C3-14 alkyl and C3-14 alkenyl;
• and
• m is selected from 5, 6, 7, 8, 9, 10, 11, 12, and 13.